Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.280
+0.080 (2.50%)
At close: Nov 20, 2024, 4:00 PM
3.120
-0.160 (-4.88%)
After-hours: Nov 20, 2024, 7:59 PM EST
Grace Therapeutics Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
| Revenue | - | - | - | - | 0.2 | - | |
| Cost of Revenue | - | - | - | - | 0.08 | - | |
| Gross Profit | - | - | - | - | 0.12 | - | |
| Selling, General & Admin | 7.29 | 6.68 | 8.28 | 6.58 | 6.66 | 8.46 | |
| Research & Development | 8.72 | 4.59 | 9.93 | 5.56 | 4.17 | 15.97 | |
| Operating Expenses | 16.01 | 11.28 | 18.21 | 12.14 | 10.84 | 24.44 | |
| Operating Income | -16.01 | -11.28 | -18.21 | -12.14 | -10.72 | -24.44 | |
| Interest Expense | - | - | - | - | -0.26 | -0.25 | |
| Interest & Investment Income | 0.57 | 0.91 | 0.25 | 0.08 | 0.11 | 0.34 | |
| Currency Exchange Gain (Loss) | -0.01 | -0.02 | -0.07 | -0.3 | -0.68 | -0 | |
| Other Non Operating Income (Expenses) | 1.26 | -2.73 | 0.01 | 5.34 | -2.43 | -1.16 | |
| EBT Excluding Unusual Items | -14.19 | -13.11 | -18.02 | -7.02 | -13.98 | -25.51 | |
| Merger & Restructuring Charges | - | -1.49 | -33.51 | -3.2 | - | - | |
| Asset Writedown | -0.09 | -0.09 | -0.44 | -0.25 | -5.7 | - | |
| Pretax Income | -14.28 | -14.69 | -51.97 | -10.47 | -19.68 | -25.51 | |
| Income Tax Expense | -2.67 | -1.83 | -9.54 | -0.65 | - | - | |
| Net Income | -11.61 | -12.85 | -42.43 | -9.82 | -19.68 | -25.51 | |
| Net Income to Common | -11.61 | -12.85 | -42.43 | -9.82 | -19.68 | -25.51 | |
| Shares Outstanding (Basic) | 12 | 10 | 7 | 6 | 2 | 2 | |
| Shares Outstanding (Diluted) | 12 | 10 | 7 | 6 | 2 | 2 | |
| Shares Change (YoY) | 54.23% | 28.16% | 21.09% | 148.46% | 40.25% | 55.80% | |
| EPS (Basic) | -1.01 | -1.35 | -5.71 | -1.60 | -7.96 | -14.48 | |
| EPS (Diluted) | -1.01 | -1.35 | -5.71 | -1.60 | -7.96 | -14.48 | |
| Free Cash Flow | -11.84 | -12.36 | -15.93 | -17.23 | -14.39 | -23.27 | |
| Free Cash Flow Per Share | -1.03 | -1.30 | -2.14 | -2.81 | -5.82 | -13.21 | |
| Gross Margin | - | - | - | - | 61.22% | - | |
| Operating Margin | - | - | - | - | -5467.35% | - | |
| Profit Margin | - | - | - | - | -10039.80% | - | |
| Free Cash Flow Margin | - | - | - | - | -7340.82% | - | |
| EBITDA | -16 | -11.27 | -18.08 | -11.22 | -9.79 | -22.12 | |
| D&A For EBITDA | 0.01 | 0.01 | 0.12 | 0.92 | 0.92 | 2.32 | |
| EBIT | -16.01 | -11.28 | -18.21 | -12.14 | -10.72 | -24.44 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.